FDA Responds to Biohaven's VYGLXIA Application for Spinocerebellar Ataxia Treatment Biohaven's VYGLXIA (troriluzole) application for treating Spinocerebellar Ataxia faced a complete response from the FDA, igniting concerns.

FDA Responds to Biohaven's VYGLXIA Application for Spinocerebellar Ataxia Treatment #United_States #Biohaven #New_Haven #Spinocerebellar_Ataxia #VYGLXIA

Biohaven Announces Promising Financial Results and Future Developments in Innovative Therapies Biohaven Ltd. shares significant Q2 2025 financial results, showcasing advancements in therapies for conditions like neurodegeneration and immunology.

Biohaven Announces Promising Financial Results and Future Developments in Innovative Therapies #United_States #Biohaven #New_Haven #BHV-8000 #VYGLXIA